A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%

NCT02173249 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
11
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Aciex Therapeutics, Inc.